



19 August 2019

PLACEMENT

Notice Under ASX Listing Rule 3.10.5 and Section 708A of the Corporations Act and Appendix 3B

Inca Minerals Limited (Inca or Company) is pleased to advise the Company has completed a capital raising of \$150,000 (before raising costs) through the issue of 40,000,000 fully paid ordinary shares at an issue price of 0.375 of a cent per share.

The funds raised will be used for Company administration in Australia and exploration at the Company's Australian projects and in general for working capital.

The requisite Appendix 3B is attached to this announcement and Inca provides the following information pursuant to ASX Listing Rule 3.10.5 and Section 708A(5)(e) of the Corporations Act.

This placement was made to Acuity Capital Investment Management Pty Ltd without disclosure under Part 6D.2 of the Corporations Act, using Inca's ASX 7.1 (15%) capacity, under Section 708(8) of the Corporations Act. These shares rank equally with all other fully paid issued ordinary shares (ASX: ICG).

As at the date of this notice Inca has complied with:

- (a) The provisions of Chapter 2M of the Corporations Act;
- (b) Section 674 of the Corporations Act; and

there is no excluded information for the purposes of Sections 708A(7) and (8) of the Corporations Act.

Malcolm Smartt

Company Secretary

Website: www.incaminerals.com.au

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

	of entity Minerals Limited	
inca i	VIIITETAIS EITITEEA	
ABN		
128 51	12 907	
·	he entity) give ASX the following	g information.
You mu	ust complete the relevant sections (attac	th sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares (ASX: ICG)
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	40,000,000 ICG Shares
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary rank equally with all other issued fully paid ordinary shares (ASX: ICG).

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes – see above.
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	40,000,000 at \$.00375
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To fund exploration at the Company's projects and working capital as warranted.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	N/a
6c	Number of *securities issued without security holder approval under rule 7.1	40,000,000 FPOS
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A.	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A.	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining Issue Capacity	Rule 7.1: 264,592,546
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	Estimated 22 August 2019	
			I
8	Number and ⁺ class of all ⁺ securities quoted on ASX	Number 3,134,350,366	+Class Fully paid ordinary shares.
	(including the +securities in section 2 if applicable)	408,662,207	Options (Ex. 7/08/2020)
	,		
		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	Nil	N/A
10	Dividend policy (in the case of a	All charge and options ran	nk equally from issue date
10	trust, distribution policy) on the	with all existing quot	ed fully paid ordinary
	increased capital (interests)	shares(ICG).	

Part 2 - Pro rata issue

11	Is security holder approval N/A required?
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities N/A will be offered
14	⁺ Class of ⁺ securities to which the offer relates
15	⁺ Record date to determine N/A entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their
	entitlements are to be dealt with. Cross reference: rule 7.7.
19	Closing date for receipt of N/A acceptances or renunciations
20	Names of any underwriters N/A
21	Amount of any underwriting fee N/A or commission
22	Names of any brokers to the issue N/A
23	Fee or commission payable to the broker to the issue

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities Type of *securities 34 (tick one) (a) +Securities described in Part 1 (b) All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of the 35 additional *securities, and the number and percentage of additional *securities held by those holders If the *securities are *equity securities, a distribution schedule of the additional 36 *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional *securities 37 Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A
39	⁺ Class of ⁺ securities for which quotation is sought	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (<i>including</i> the *securities in clause 38)	N/A	

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 19 August 2019

(Company Secretary)

Print name: Malcolm Smartt

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base fig capacity is calculated	ure from which the placement
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	2,592,788,159
Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval	70,038,998 (issued 3/12/2018); 10,000,000 (issued 7/11/2018); 12,900,000 (issued 1/10/2018); and 32,961,000 (issued 19/9/2018) being shortfall securities from a non-renounceable pro-rata entitlement offer pursuant to a Prospectus dated 2/8/2018). 136,128,818 (issued 5/9/2018 under a non-renounceable pro-rata entitlement offer pursuant to a Prospectus dated 2/8/2018). 27,500,000 (issued 2/8/2018 with shareholder approval at 30/11/2018 AGM). 5,500,000 FPOS issued 6/06/2019 (Issued with shareholder approval GM 31/May/19).
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items	
Subtract the number of fully paid †ordinary securities cancelled during that 12 month period	0
"A"	2,885,316,975

o4/o3/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B" 0.15	
	[Note: this value cannot be changed]
Multiply "A" by 0.15	432,797,546
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	

Insert number of +equity securities issued or agreed to be issued in that 12 month	61,565,000 FPOS issued 2/05/2019.
period not counting those issued:	46,640,000 options issued 2/05/2019.
• Under an exception in rule 7.2	2,500,000 FPOS as part of this
Under rule 7.1A	announcement.
With security holder approval under	8,750,000 FPOS and 8,750,000 options.
rule 7.1 or rule 7.4	40,000,000 FPOS as per this announcement
Note:	
This applies to equity securities, unless specifically excluded – not just ordinary securities	
 Include here (if applicable) the securities the subject of the Appendix 	
 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	168,205,000

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15	432,797,546
Note: number must be same as shown in Step 2	
Subtract "C"	168,205,000
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	264,592,546

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A"	N/A
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	N/A
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items	

04/03/2013 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.